Scienture (SCNX) to Release Earnings on Monday

Scienture (NASDAQ:SCNX) is projected to issue its Q2 2026 results before the market opens on Monday, August 17th. Analysts expect the company to announce earnings of ($0.09) per share and revenue of $1.9640 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Monday, August 17, 2026 at 4:00 PM ET.

Scienture (NASDAQ:SCNX) last released its quarterly earnings data on Friday, May 15th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.15. The firm had revenue of $0.06 million for the quarter, compared to analysts’ expectations of $0.40 million.

Scienture Stock Performance

Shares of SCNX stock opened at $0.38 on Monday. The company has a market cap of $15.44 million, a P/E ratio of -0.15 and a beta of 3.26. The firm has a fifty day moving average price of $0.37 and a 200 day moving average price of $0.40. Scienture has a 12 month low of $0.24 and a 12 month high of $2.60.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Scienture stock. Virtu Financial LLC bought a new stake in Scienture Holdings, Inc. (NASDAQ:SCNX) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 89,930 shares of the company’s stock, valued at approximately $46,000. Virtu Financial LLC owned about 0.22% of Scienture at the end of the most recent reporting period. Institutional investors and hedge funds own 5.68% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Scienture in a report on Wednesday, June 24th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, Scienture has an average rating of “Hold” and a consensus target price of $1.50.

Scienture Company Profile

Scienture Holdings, Inc engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.